Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 10, 2008, Pages 1745-1752

  Johnson, Lance A ^a   Altenburg, Michael K ^a   Walzem, Rosemary L ^b   Scanga, Lori T ^a   Maeda, Nobuyo ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Animal models; Apolipoprotein B100; Atherosclerosis; Familial hypercholesterolemia; Lipoprotein clearance

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B100 BETA; APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN B MRNA EDITING ENZYME; CYTIDINE DEAMINASE; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIET; GENE MUTATION; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ANIMAL; BINDING SITE; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; FAT INTAKE; GENETICS; LIVER CELL; METABOLISM; MOUSE MUTANT; MUTATION; PARTICLE SIZE; PERITONEUM MACROPHAGE; PROTEIN BINDING; PROTEIN CONFORMATION; TIME;

ANIMALS; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; BINDING SITES; CYTIDINE DEAMINASE; DIETARY FATS; DISEASE MODELS, ANIMAL; HEPATOCYTES; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PARTICLE SIZE; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, LDL; TIME FACTORS;

EID: 53449087940     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.169680     Document Type: Article

References (38)

1. Davidson NO, Anant S, MacGinnitie AJ. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr Opin Lipidol. 1995;6:70-74.
2. Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993;34:1367-1383.
3. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest. 1998;101:1084-1093.
4. Toth LR, Smith TJ, Jones C, de Silva HV, Smithies O, Maeda N. Two distinct apolipoprotein B alleles in mice generated by a single 'in-out' targeting. Gene. 1996;178:161-168.
5. Rauh G, Keller C, Schuster H, Wolfram G, Zollner N. Familial defective apolipoprotein B-100: a common cause of primary hypercholesterolemia. Clin Investig. 1992;70:77-84.
6. Hirano K, Young SG, Farese RV, Ng J, Sande E, Warburton C, Powell-Braxton LM, Davidson NO. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J Biol Chem. 1996;271:9887-9890.
7. Morrison JR, Pászty C, Stevens ME, Hughes SD, Forte T, Scott J, Rubin EM. Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism. Proc Natl Acad Sci U S A. 1996;93:7154-7159.
8. Folch J, Lees M, Slaone Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
9. Li X, Catalina F, Grundy SM, Patel S. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J Lipid Res. 1996;37:210-220.
10. Véniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, Hellerstein MK, Rudel LL, Walzem RL, Young SG. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest. 2000;106:1501-1510.
11. Altenburg M, Arbones-Mainar J, Johnson L, Wilder J, Maeda N. Human LDL receptor enhances sequestration of apoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice. Arterioscler Thromb Vasc Biol. 2008;28:1104-1110.
12. Farkas MH, Swift LL, Hasty AH, Linton MF, Fazio S. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem. 2003;278:9412-9417.
13. Stephan ZF, Yurachek EC. Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL. J Lipid Res. 1993;34:325-330.
14. Atsma DE, Kempen HJ, Nieuwenhuizen W, van 't Hooft FM, Pauwels EK. Partial characterization of low density lipoprotein preparations isolated from fresh and frozen plasma after radiolabeling by seven different methods. J Lipid Res. 1991;32:173-181.
15. Chen GC, Lau K, Hamilton RL, Kane JP. Differences in local conformation in human apolipoprotein B-100 of plasma low density and very low density lipoproteins as identified by cathepsin D. J Biol Chem. 1991;266:12581-12587.
16. Chen GC, Zhu S, Hardman DA, Schilling JW, Lau K, Kane JP. Structural domains of human apolipoprotein B-100. Differential accessibility to limited proteolysis of B-100 in low density and very low density lipoproteins. J Biol Chem. 1989;264:14369-14375.
17. Bradley WA, Hwang SL, Karlin JB, Lin AH, Prasad SC, Gotto AM Jr, Gianturco SH. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem. 1984;259:14728-14735.
18. Brown MS, Goldstein JL. Familial hypercholesterolemia: genetic, biochemical and pathophysiologic considerations. Adv Intern Med. 1975;20:273-296.
19. Powell-Braxton L, Veniant M, Latval RD, Hiran KL, Won WB, Ross I, Dybdal N, Zlot CH, Young SG, Davidson NO A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med. 1998;4:934-938.
20. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883-893.
21. Havel RJ, Kita T, Kotite L, Kane JP, Hamilton RL, Goldstein JL, Brown MS. Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia. Arteriosclerosis. 1982;2:467-474.
22. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007;117:94-98.
23. Veniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Invest. 1998;102:1559-1568.
24. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res. 2005;46:872-884.
25. Abrams JJ, Grundy SM, Ginsberg H. Metabolism of plasma triglycerides in hypothyroidism and hyperthyroidism in man. J Lipid Res. 1981;22:307-322.
26. Stalenhoef AF, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc Natl Acad Sci U S A. 1984;81:1839-1843.
27. Borchardt RA, Davis RA. Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion. J Biol Chem. 1987;262:16394-16402.
28. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000;105:521-532.
29. Gillian-Daniel DL, Bates PW, Tebon A, Attie AD. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc Natl Acad Sci U S A. 2002;99:4337-4342.
30. Larsson SL, Skogsberg J, Björkegren J. The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver. J Biol Chem. 2004;279:831-836.
31. Williams KJ, Brocia RW, Fisher EA. The unstirred water layer as a site of control of apolipoprotein B secretion. J Biol Chem. 1990;265:16741- 16744.
32. Blasiole DA, Oler AT, Attie AD. Regulation of ApoB secretion by the LDL receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB. J Biol Chem. In press.
33. -/- mice is regulated by the LDL receptor. J Lipid Res. 2004;45:1649-1659.
34. Borén J, Ekström U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem. 2001;276:9214-9218.
35. Benn M, Nordestgaard BG, Jensen JS, Nilausen K, Meinertz H, Tybjaerg-Hansen A. Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor. J Biol Chem. 2005;280:21052-21060.
36. Schaefer JR, Scharnagl H, Baumstark MW, Schweer H, Zech LA, Seyberth H, Winkler K, Steinmetz A, März W. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vasc Biol. 1997;17:348-353.
37. Gaffney D, Forster L, Caslake MJ, Bedford D, Stewart JP, Stewart G, Wieringa G, Dominiczak M, Miller JP, Packard CJ. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis. 2002;162:33-43.
38. Chatterton JE, Phillips ML, Curtiss LK, Milne R, Fruchart JC, Schumaker VN. Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. J Lipid Res. 1995;36:2027-2037.